Trial Profile
A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 and GT3 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms C-SWIFT
- Sponsors Merck Sharp & Dohme Corp.
- 18 Mar 2017 Results assessing antiviral effect of Zepatier and sofosbuvir using viral dynamics model, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 22 Oct 2016 Results assessing efficacy and safety published in the Hepatology.
- 17 Apr 2016 Re-treatment final results (n=25) presented at The International Liver Congress™ 2016